Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 4Gynecologic 3Thoracic 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × belinostat × Genitourinary × Clear all
NCT00421889 2015-07-28

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Valerio Therapeutics

Phase 1/2 Completed
80 enrolled 19 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡